Lewko W M, Nayak S K, Hubbard W J, Thurman G B, Oldham R K
Biotherapeutics, Inc., Franklin, TN 37065-1676.
Mol Biother. 1989;1(5):256-60.
Chemosensitivity assays were carried out as part of a tumor acquisition, propagation, and preservation program for cancer biotherapy. In addition to biopsy specimens, tumor cells propagated in culture or tumor xenografts grown in nude mice were submitted for chemosensitivity assay when sufficient biopsy material was unavailable. Chemosensitivity was tested utilizing the adhesive tumor cell culture system. A total of 154 specimens was submitted for testing; 96 specimens were assayed. Success rates were 55% for primary cancer biopsies, 67% for metastases, 69% for xenografts, and 70% for cell lines. There were no significant differences evident when the sensitivity to drugs of tumor cells originating from biopsies, xenografts, or tissue culture were compared. Sufficient data were available for 18 patients to compare clinical results of drug treatment with predictive results from the chemo-sensitivity assay. Assay results indicating insensitivity appeared to predict resistance; however, assays indicating sensitivity were not predictive. These results suggest that propagated tumor material, such as xenografts and cultured cell lines, may be useful when biopsy tissue is not available.
作为癌症生物治疗肿瘤获取、增殖和保存计划的一部分，进行了化学敏感性测定。除活检标本外，当没有足够的活检材料时，在培养物中增殖的肿瘤细胞或在裸鼠中生长的肿瘤异种移植物也被送去进行化学敏感性测定。利用粘附性肿瘤细胞培养系统测试化学敏感性。总共提交了154个标本进行测试；其中96个标本进行了测定。原发性癌活检的成功率为55%，转移灶为67%，异种移植物为69%，细胞系为70%。比较源自活检、异种移植物或组织培养的肿瘤细胞对药物的敏感性时，没有明显差异。有足够的数据可用于18名患者，以比较药物治疗的临床结果与化学敏感性测定的预测结果。显示不敏感的测定结果似乎可预测耐药性；然而，显示敏感的测定结果并无预测性。这些结果表明，当没有活检组织时，增殖的肿瘤材料，如异种移植物和培养的细胞系，可能会有用。
